| 前收盘价格 | 34.46 |
| 收盘价格 | 34.68 |
| 成交量 | 2,075,284 |
| 平均成交量 (3个月) | 2,774,411 |
| 市值 | 9,882,598,400 |
| 市盈率 (P/E TTM) | 20.06 |
| 预期市盈率 (P/E Forward) | 15.85 |
| 价格/销量 (P/S) | 4.76 |
| 股市价格/股市净资产 (P/B) | 4.35 |
| 52周波幅 | |
| 利润日期 | 28 Apr 2025 - 2 May 2025 |
| 营业毛利率 | 24.04% |
| 营业利益率 (TTM) | 28.84% |
| 稀释每股收益 (EPS TTM) | 1.76 |
| 季度收入增长率 (YOY) | 18.20% |
| 季度盈利增长率 (YOY) | 63.50% |
| 总债务/股东权益 (D/E MRQ) | 9.62% |
| 流动比率 (MRQ) | 3.63 |
| 营业现金流 (OCF TTM) | 699.97 M |
| 杠杆自由现金流 (LFCF TTM) | 464.22 M |
| 资产报酬率 (ROA TTM) | 14.64% |
| 股东权益报酬率 (ROE TTM) | 23.13% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Exelixis, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.3
| 分析师共识 | 1.5 |
| 内部交易活动 | 3.0 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.30 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.84% |
| 机构持股比例 | 92.05% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (Citigroup, 27.44%) | 购买 |
| 中 | 39.00 (10.45%) | |
| 低 | 29.00 (Barclays, -17.87%) | 保留 |
| 29.00 (Stephens & Co., -17.87%) | 保留 | |
| 平均值 | 37.57 (6.40%) | |
| 总计 | 8 购买, 6 保留 | |
| 平均价格@调整类型 | 33.75 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Mar 2025 | 40.00 (13.28%) | 购买 | 36.84 |
| 13 Feb 2025 | 40.00 (13.28%) | 购买 | 34.49 | |
| RBC Capital | 13 Mar 2025 | 40.00 (13.28%) | 购买 | 36.80 |
| Wells Fargo | 24 Feb 2025 | 36.00 (1.95%) | 保留 | 37.13 |
| Barclays | 13 Feb 2025 | 29.00 (-17.87%) | 保留 | 34.49 |
| Citigroup | 12 Feb 2025 | 45.00 (27.44%) | 购买 | 32.80 |
| Guggenheim | 12 Feb 2025 | 42.00 (18.95%) | 购买 | 32.80 |
| Piper Sandler | 12 Feb 2025 | 38.00 (7.62%) | 购买 | 32.80 |
| Stephens & Co. | 12 Feb 2025 | 29.00 (-17.87%) | 保留 | 32.80 |
| 27 Jan 2025 | 29.00 (-17.87%) | 保留 | 32.73 | |
| Stifel | 12 Feb 2025 | 36.00 (1.95%) | 保留 | 32.80 |
| UBS | 28 Jan 2025 | 34.00 (-3.71%) | 保留 | 32.60 |
| JMP Securities | 27 Jan 2025 | 41.00 (16.11%) | 购买 | 32.73 |
| 23 Jan 2025 | 41.00 (16.11%) | 购买 | 34.13 | |
| Morgan Stanley | 27 Jan 2025 | 40.00 (13.28%) | 购买 | 32.73 |
| Truist Securities | 27 Jan 2025 | 43.00 (21.78%) | 购买 | 32.73 |
| Oppenheimer | 24 Jan 2025 | 33.00 (-6.54%) | 保留 | 32.38 |
| 16 Jan 2025 | 41.00 (16.11%) | 购买 | 36.55 | |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合